News PTC shares soar after SMA drug data impresses market After failing three times to bring their Duchenne therapy to the US market, PTC Therapeutics might be on verge of a breakthrough in the SMA field.
News Regeneron gets long-awaited FDA okay for myeloma drug Regeneron's bid to join the crowded US market for BCMA-targeted bispecific antibodies for multiple myeloma has finally been realised.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face